Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

0,916

Operating loss (2,345) (2,145) (11,348) (10,295)

Other income (expenses):

Interest and other

income, net 141 17 571 138

Net foreign exchange

(loss) gain (115) 85 (1,636) 90

26 102 (1,065) 228

Net loss and

comprehensive loss $(2,319) $(2,043) $(12,413) $(10,067)

Basic and diluted

loss per common share: $(0.01) $(0.02) $(0.06) $(0.12)

Weighted average number of

shares used to compute

basic and diluted loss

per common share

(in thousands) 260,836 83,669 212,449 83,440

Condensed Consolidated Balance Sheet Information

(Unaudited)

(Canadian dollars)(In thousands, except per share amounts)

December 31, December 31,

2007 2006

Cash and cash equivalents $12,859 $2,972

Total assets 14,471 4,619

Stockholders' equity 12,781 2,303

Total shares outstanding (in thousands) 260,586 83,669


'/>"/>
SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 1, 2015 ... announced the addition of the "Oxidative ... Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen ... End Users - Global Forecast to 2020" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , The ...
(Date:6/1/2015)... June 1, 2015 GenomeDx Biosciences ... analysis platform, successfully classified various subtypes of ... of certain biomarkers, including one type associated ... unique genomic signature has potential as a ... chemotherapy in patients with muscle-invasive bladder cancers ...
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 Regis ... and manufacturing of chiral stationary phases (CSPs) for ... for its current and presenting solutions for new ... its portfolio. This valuable addition to its core ... effective advantage that can tackle projects for the ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... Blood ... Expertise, PALO ALTO, Calif., May 29 Pelikan Technologies ... announced the appointment of Dennert (Denny) Ware to its,board of ... of Kinetic Concepts, Inc. (KCI), a global medical,technology company, Mr. ...
... China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. ... of the leading plasma-based pharmaceutical companies in the,People,s ... announced that the,Company has been approved by the ... commence the production of Human Albumin 12.5g/vial (25%,50 ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier ... oncologists and the pharmaceutical industry,today announced that, effective ... will join Clarient as Senior Vice President and ... years experience as a public,company CFO in life ...
Cached Biology Technology:Pelikan Technologies Appoints Denny Ware to Board of Directors 2Pelikan Technologies Appoints Denny Ware to Board of Directors 3China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 2China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml) 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 2Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 3Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 4Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer 5
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 21 June, 2010 The Editors of the leading ... announce that the third Ahmed Zewail Prize in Molecular Sciences ... University of California, Berkeley, USA, for his outstanding contributions to ... monetary award of $20,000 and will be presented during the ...
... technology university, Nanyang Technological University (NTU), and Israel,s ... today announced a new collaboration to jointly offer ... The NTU-Technion Joint PhD degree programme is a ... Materials Science and Bioengineering. Significantly, the joint PhD ...
... Elsevier announced the launch of PeerChoice, a new pilot ... reviewers now have the freedom to choose which articles they ... and interest, efficiency and effectiveness of the peer review process ... three months, starting in June. PeerChoice reverses ...
Cached Biology News:Elsevier announces the winner of the Ahmed Zewail prize in molecular sciences 2NTU ramps up collaboration with Israel's top university 2NTU ramps up collaboration with Israel's top university 3Elsevier pilots PeerChoice in Chemical Physics Letters 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... cyclin required for G1-phase progression and is ... cyclin D2 can phosphorylate pRB when associated ... Human, Mouse, and Rat. Others-not tested. ... suited for neutralization of cyclin D2 activity ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: